Telix Pharmaceuticals Limited announced on June 21 it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business.
Lightpoint Medical is a technology leader in precision-guided robotic cancer surgery. The company develops and markets miniaturized imaging and sensing tools for advanced intra-operative cancer detection. Lightpoint Medical has developed SENSEI, a miniaturized surgical gamma probe for minimally-invasive and robot-assisted surgery.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is headquartered in Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan.
According to its 2022 annual report, Telix generated revenues of $160.1 million during FY 2022, which represents a 20-fold increase compared to the $7.6 million generated in 2021. This significant growth was primarily driven by the successful commercial launch of Illuccix®.
The Lightpoint SENSEI business will be integrated into Telix and operate as a new surgeon-focused business unit, driving the ongoing development of SENSEI combined with Telix’s pharmaceutical pipeline. The new business unit will support development of Telix’s other related medical device and software technologies, such as Telix’s recently acquired artificial intelligence platform. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 57th Medical Devices transaction of the year and the 28th of Q2:23. This also marks Telix’s first acquisition of the year. In November 2022, Telix announced its acquisition of Optimal Tracers in Sacramento, California for an undisclosed price.
